How Many Bio-Techne Corporation (NASDAQ:TECH)’s Analysts Are Bearish?

September 16, 2018 - By Andrea Bass

Bio-Techne Corporation (NASDAQ:TECH) LogoInvestors sentiment decreased to 1.01 in 2018 Q2. Its down 0.31, from 1.32 in 2018Q1. It dived, as 24 investors sold Bio-Techne Corporation shares while 98 reduced holdings. 39 funds opened positions while 84 raised stakes. 37.29 million shares or 6.51% more from 35.01 million shares in 2018Q1 were reported.
Credit Suisse Ag invested 0.01% in Bio-Techne Corporation (NASDAQ:TECH). Old Fincl Bank In invested 0.02% in Bio-Techne Corporation (NASDAQ:TECH). Geode Cap Mngmt Llc reported 353,876 shares. Sandhill Cap Lc reported 154,996 shares. Ny State Common Retirement Fund has 385,881 shares. Ameritas Invest holds 11,172 shares. Neuberger Berman Limited Liability Co holds 1.58 million shares or 0.26% of its portfolio. Parkside National Bank & Trust Tru holds 0.03% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 563 shares. Nuveen Asset Ltd invested in 0% or 2,021 shares. Qs Lc accumulated 0% or 1,013 shares. Df Dent & Company Inc holds 512,002 shares or 1.71% of its portfolio. Art Advsr Lc accumulated 2,400 shares. Paradigm Asset Management Commerce Ltd Liability stated it has 300 shares. Trust Department Mb Bancorp N A invested in 53 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt Systems has 10,142 shares.

Since May 4, 2018, it had 0 insider buys, and 4 sales for $4.27 million activity. Shares for $1.28M were sold by Kummeth Charles R. on Thursday, June 7. $164,932 worth of Bio-Techne Corporation (NASDAQ:TECH) was sold by Eansor Norman David. Another trade for 5,000 shares valued at $942,334 was made by BAUMGARTNER ROBERT V on Friday, August 24.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 4 analysts covering Bio-Techne (NASDAQ:TECH), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Bio-Techne had 5 analyst reports since May 3, 2018 according to SRatingsIntel. The company was maintained on Thursday, May 3 by Leerink Swann. Deutsche Bank maintained the shares of TECH in report on Thursday, May 3 with “Buy” rating. The stock of Bio-Techne Corporation (NASDAQ:TECH) has “Hold” rating given on Wednesday, June 27 by Deutsche Bank. The rating was maintained by Citigroup with “Buy” on Thursday, August 9. Below is a list of Bio-Techne Corporation (NASDAQ:TECH) latest ratings and price target changes.

09/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $160 New Target: $205 Maintain
27/06/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $165 Downgrade
15/06/2018 Broker: Argus Research Rating: Buy New Target: $185 Initiates Coverage On
03/05/2018 Broker: Leerink Swann Rating: Buy New Target: $160.0000 Maintain
03/05/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $167 New Target: $165 Maintain

The stock increased 1.20% or $2.37 during the last trading session, reaching $199.81. About 249,874 shares traded or 22.77% up from the average. Bio-Techne Corporation (NASDAQ:TECH) has risen 60.17% since September 16, 2017 and is uptrending. It has outperformed by 44.55% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $7.54 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 60.37 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

More notable recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Marketwatch.com which released: “Stock market logs weekly loss as Trump hints at more China tariffs” on September 07, 2018, also Etftrends.com with their article: “Tech ETFs and Nasdaq Falter on Sell-Off” published on September 05, 2018, Cnbc.com published: “Nasdaq and S&P 500 reach all-time highs as Amazon, Alphabet and Apple rally” on August 29, 2018. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At …” published on September 11, 2018 as well as Cnbc.com‘s news article titled: “Tech will continue to drive Nasdaq higher: Strategist” with publication date: August 27, 2018.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.